The U.S. Food and Drug Administration (FDA) has intensified its crackdown on the illicit sale of weight loss medications, issuing a series of warning letters to companies marketing unapproved GLP-1 receptor agonists. The agency is targeting a growing network of sellers who distribute these potent metabolic drugs—and their dual and triple agonist variants—without regulatory oversight, often using deceptive labeling to bypass federal law.
In a batch of letters published on April 7, the FDA identified several firms selling these products online, including through platforms like eBay. The agency warns that these unapproved weight loss drugs pose significant public health risks, particularly when administered via injection, as they can bypass the body’s natural defenses and introduce toxins or microorganisms directly into the bloodstream.
This latest enforcement action is part of a broader pattern. Over the past year, the U.S. Food and Drug Administration has issued dozens of similar warnings to companies attempting to capitalize on the high demand for GLP-1 medications. The agency is specifically focusing on the danger of “research chemicals” being sold as medical treatments.
The ‘Research Only’ Loophole and Public Risk
Many of the targeted companies attempted to shield themselves from regulation by labeling their products for “laboratory research purposes only” and stating they are “not for human consumption, medical use or veterinary use.” However, the FDA found that the companies’ own websites provided evidence that the products were intended for human use as drugs to affect the structure or function of the body.
Among the firms cited are Prime Sciences, Lovega, Gram Peptides, FormPour, Guangzhou Huli Technology, Mile High Compounds, and PekCura Labs. The agency noted that these products—ranging from GLP-1 agonists to complex triple agonists (GLP-1/GIP/glucagon)—are “unapproved new drugs” because they are not generally recognized as safe and effective (GRASE) for the conditions suggested in their marketing.
In a specific warning to Guangzhou Huli, based in Chicago, the FDA highlighted the “Googeer GLP-1 Weight Control Oral Solution,” noting that no approved application is in effect for the product. The agency flagged Prime Sciences, Lovega, and Gram Peptides for selling bacteriostatic water alongside these peptides. Because this water is used to reconstitute drugs for injection, the FDA classified the water itself as an unapproved drug.
The danger of these unapproved weight loss drugs is not merely regulatory. As the FDA wrote in its letter to Prime Sciences, “Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.”
Manufacturing Failures and Patient Safety
While the crackdown on unapproved drugs dominates the headlines, the FDA’s recent warnings too targeted established medical device manufacturers for critical safety lapses. Medline Industries received a warning letter after investigators found the company failed to meet current good manufacturing Practices (CGMP), specifically regarding its risk-based corrective and preventive action (CAPA) procedures.
The agency’s concerns centered on NAMIC Angiographic Control Syringes used in cardiovascular procedure kits. The FDA noted that Medline failed to respond adequately to a spike in complaints in June 2023, where syringes were disconnecting from manifolds due to excess silicone. Despite the company’s internal evaluation labeling the risk as “low,” the FDA pointed out that this contradicted the company’s own design failure analysis, which identified “air embolism” as a high-severity risk for loose connections.
The real-world impact of these failures was documented in medical device reports (MDR). The FDA cited 221 complaints and 177 MDRs, including one instance where air was injected into a patient and another involving the biohazard exposure of a clinician. Medline was also cited for failing to maintain equipment maintenance schedules and failing to ensure device inputs met design outputs.
Summary of Recent FDA Enforcement Actions
| Entity | Primary Violation | Key Risk/Issue |
|---|---|---|
| GLP-1 Marketers | Unapproved New Drugs | Contamination/Toxicity in injectables |
| Medline Industries | CGMP/CAPA Failures | Air embolism/Biohazard exposure |
| Ehsan Sadri, MD | Clinical Trial Protocol | Ineligible subjects/Data reliability |
Integrity Gaps in Clinical Research
The FDA also issued a warning to Dr. Ehsan Sadri, a Newport Beach-based ophthalmologist and researcher, for failing to adhere to clinical trial protocols. The agency found that Sadri enrolled subjects who did not meet the necessary eligibility criteria, including one patient who lacked a required central corneal endothelial cells (CEC) density measurement and another whose intraocular pressure (IOP) fell outside the allowed range.
When questioned via a Form 483, Sadri attributed the errors to a shortened enrollment period and delayed site activation. The FDA rejected this explanation, stating that regardless of the timeline, the investigator remains responsible for ensuring all subjects meet protocol-specified criteria to protect patient safety and the integrity of the study data.
The agency noted that two of the nine randomized subjects who received the investigational product were ineligible, raising significant concerns about the reliability of the trial’s overall results.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Always consult a licensed healthcare provider before starting any medication or weight loss regimen.
The FDA has requested that Medline Industries respond to its warning within 15 business days, ensuring compliance with the updated Quality System Management Regulation (QMSR). As the agency continues to monitor the illegal market for GLP-1 agonists, further warning letters and potential seizures of unapproved products are expected as part of its ongoing public health mandate.
We invite readers to share their thoughts or experiences with regulatory transparency in the comments below.
